Lotus Eye Hospital and Institute Latest Share Price (LOTUSEYE)
TODAY IN ONE LINE
LOTUSEYE slipped 0.5% on light volume, in line with Nifty's 0.1% move, supported by recent strong earnings.
With a market cap of ₹245.81 Cr., it trades at a P/E of 2925.00. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Lotus Eye Hospital and Institute flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.26x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Poor Capital ReturnsLow ROE of 0.1%
Latest Lotus Eye Hospital and Institute News
What changed recently?
Recent events, corporate actions, and announcements.
Lotus Eye Hospital and Institute Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Lotus Eye Hospital and Institute Limited, framed against the sector median so the premium or discount is obvious at a glance.
Lotus Eye Hospital and Institute Limited trades at a P/E of 2925.00× and P/B of 4.05×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Lotus Eye Hospital and Institute Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Lotus Eye Hospital and Institute Limited — derived from the latest tape, not yesterday's close.
Lotus Eye Hospital and Institute Limited last traded at ₹117.24 with an intraday range of ₹116.7–₹118.49 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹117.24| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 121.83 | +4.59 | +3.92% |
| R3 | 120.04 | +2.80 | +2.39% |
| R2 | 119.27 | +2.03 | +1.73% |
| R1 | 118.25 | +1.01 | +0.86% |
| PIVOT | 117.48 | 0.24 | 0.20% |
| CURRENT | 117.24 | — | — |
| S1 | 116.46 | -0.78 | -0.66% |
| S2 | 115.69 | -1.55 | -1.32% |
| S3 | 114.67 | -2.57 | -2.19% |
| S4 | 112.88 | -4.36 | -3.72% |
LOTUSEYE is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹117.01–₹117.25
Trading Inside opening range
Lotus Eye Hospital and Institute Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Lotus Eye Hospital and Institute Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Lotus Eye Hospital and Institute Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹245.81 Cr. and reported EPS of ₹0.04.
Lotus Eye Hospital and Institute segment analysis : revenue and profit mix.
Disclosed business segments at Lotus Eye Hospital and Institute with their share of revenue and profit, switchable between consolidated and standalone reporting.
Lotus Eye Hospital and Institute discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Lotus Eye Hospital and Institute Limited.
Our AI distills the core fundamental drivers supporting Lotus Eye Hospital and Institute Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Lotus Eye Hospital and Institute Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Niche specialty eye-care brand with advanced surgical capabilities and comprehensive services.
TTM revenue growth of 18.2% demonstrates strong top-line momentum in healthcare sector.
Minimal leverage with debt-to-equity of 0.0026, fortress-like balance sheet strength.
Net profit margin of 14.97% TTM, competitive within specialty healthcare segment.
Positive operating cash flow of ₹0.51 Cr in latest quarter, solid earnings quality.
Key Risks.
Operating margin of 6.29% TTM indicates profitability challenges versus peer benchmarks.
Extreme P/E valuation of 3,184.25x TTM, fundamentally unsustainable and speculative.
ROE of 0.13% and ROCE of 1.16% signal critically weak capital efficiency.
Latest quarterly EPS declined 12.6% YoY despite revenue growth, earnings volatility.
Promoter holding fell from 58.17% to 40.14%, indicating significant shareholder dilution.
Flip Conditions.
Valuation risk. a P/E above 3803 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Lotus Eye Hospital and Institute Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Lotus Eye Hospital and Institute Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Lotus Eye Hospital and Institute Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Lotus Eye Hospital and Institute Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Lotus Eye Hospital and Institute Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Lotus Eye Hospital and Institute Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Lotus Eye Hospital and Institute Limited stood at 46.7% of traded volume, against a 20-day average of 55.9%.
Lotus Eye Hospital and Institute announcements: results, concalls, ratings, M&A.
Filings Lotus Eye Hospital and Institute sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Lotus Eye Hospital and Institute files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 46 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and…
Trading Window
Lotus Eye Hospital and Institute Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider…
Disclosure under SEBI Takeover Regulations
Lotus Eye Hospital and Institute Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange…
Updates
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange regarding the financial results for the period ended March 31, 2026 in…
Copy of Newspaper Publication
LOTUSEYE: Lotus Eye Hospital and Institute Limited has informed the Exchange about Copy of Newspaper Publication regarding the Standalone Audited…
Lotus Eye Hospital and Institute dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Lotus Eye Hospital and Institute has declared, sequenced by announce and record date.
Lotus Eye Hospital and Institute corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Lotus Eye Hospital and Institute Limited: business, sector, key facts.
What Lotus Eye Hospital and Institute Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Lotus Eye Hospital and Institute Limited operates in the Hospital industry under the Healthcare sector, listed as NSE: LOTUSEYE, BSE: 532998.
Lotus Eye Hospital and Institute Limited is a prominent specialty eye care hospital in India, established in 1989 and headquartered in Coimbatore. The hospital offers a comprehensive range of ophthalmic services, catering to diverse patient needs and encompassing various subspecialties.
Their surgical services are extensive, including a wide array of refractive procedures such as ReLEx SMILE lasik, LASIK eye surgery, epilasik, and Intralase, alongside advanced cataract surgery techniques like robotic femto laser cataract surgery, phacoemulsification, micro incision cataract surgery (MICS), and small incision cataract surgery (SICS). They also perform a variety of corneal surgeries, including penetrating keratoplasty (PKP), deep anterior lamellar keratoplasty (DALK), and corneal patch grafts, as well as glaucoma surgeries like trabeculectomy and other procedures addressing conditions like pterygium and retinal detachments. The hospital also provides specialized pediatric eye care and squint surgery.
Beyond surgical interventions, Lotus Eye Hospital offers a full spectrum of medical treatments. This includes injections for various retinal diseases (like Avastin, Lucentis, and Eylea), management of conditions such as keratoconus, glaucoma, diabetic retinopathy, uveitis, and neuro-ophthalmological disorders. They also address common issues like computer vision syndrome and binocular vision problems.
The hospital's commitment extends beyond direct patient care. It operates an in-house eye bank, optical showroom, and pharmacy, providing patients with convenient access to essential resources. Furthermore, its commitment to education and research is evident through its operation of a research trust, offering a Bachelor of Science degree in optometry, various optical fellowship courses, and a DNB program, contributing to the advancement of ophthalmic care in India.
In summary, Lotus Eye Hospital and Institute Limited provides a holistic approach to eye care, integrating advanced surgical techniques, comprehensive medical treatments, supportive ancillary services, and educational initiatives to establish itself as a leading provider of ophthalmic services in India.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Dr Agarwal's Health Care (AGARWALEYE) Share PricePeer
- Apollo Hospitals Enterprise (APOLLOHOSP) Share PricePeer
- Artemis Medicare Services (ARTEMISMED) Share PricePeer
- Aster DM Healthcare (ASTERDM) Share PricePeer
- Fortis Healthcare (FORTIS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Lotus Eye Hospital and Institute Limited (LOTUSEYE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Lotus Eye Hospital and Institute Limited (LOTUSEYE)?
The current share price of Lotus Eye Hospital and Institute Limited (LOTUSEYE) is ₹117.24. Today, the stock has declined by ₹0.59 (0.5%), trading in a range of ₹116.70 to ₹118.49. The stock opened at ₹117.01 with a trading volume of 2,460 shares.
02Is Lotus Eye Hospital and Institute Limited stock a good investment for long-term?
Lotus Eye Hospital and Institute Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹245.81 Cr., P/E ratio of 2,925, ROE of 0.13%, and ROCE of 1.16%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Lotus Eye Hospital and Institute Limited stock?
The 52-week high price of Lotus Eye Hospital and Institute Limited (LOTUSEYE) is ₹147.00, while the 52-week low is ₹70.84. Currently trading at ₹117.24, the stock is 65.5% above its 52-week low and 20.24% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Lotus Eye Hospital and Institute Limited stock at the current price?
Whether to buy Lotus Eye Hospital and Institute Limited stock at ₹117.24 depends on multiple factors. The stock is currently trading with a P/E ratio of 2,925 and P/B ratio of 4.05. Today's performance shows a loss of 0.5%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Lotus Eye Hospital and Institute Limited and when is the next dividend?
Lotus Eye Hospital and Institute Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹117.24, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Lotus Eye Hospital and Institute Limited?
Lotus Eye Hospital and Institute Limited's key financial metrics include: P/E Ratio: 2,925, P/B Ratio: 4.05, ROE: 0.13%, ROCE: 1.16%, Dividend Yield: 0%, EPS: ₹0.04, Book Value: ₹28.23, and Debt-to-Equity: 0.26. The company's market cap stands at ₹245.81 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Lotus Eye Hospital and Institute Limited stock performing today in the market?
Lotus Eye Hospital and Institute Limited stock opened at ₹117.01 and is currently trading at ₹117.24, showing a decline of ₹0.59 (0.5%). The intraday high is ₹118.49 and low is ₹116.70. The trading volume stands at 2,460 shares, indicating moderate market participation today.
08What is the P/E ratio of Lotus Eye Hospital and Institute Limited and what does it indicate?
Lotus Eye Hospital and Institute Limited has a Price-to-Earnings (P/E) ratio of 2,925, which means investors are willing to pay 2,925.00 for every ₹1 of earnings. With an EPS of ₹0.04, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Lotus Eye Hospital and Institute Limited (LOTUSEYE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.